Cellular senescence mediates fibrotic pulmonary disease
Open accessThe DOI matches its Crossref record; 50 of the 52 references it cites were found in a registry or an index; 18 of the 31 sources its claims cite were checked for support.
Abstract
Idiopathic pulmonary fibrosis (IPF) is a fatal disease characterized by interstitial remodelling, leading to compromised lung function. Cellular senescence markers are detectable within IPF lung tissue and senescent cell deletion rejuvenates pulmonary health in aged mice. Whether and how senescent cells regulate IPF or if their removal may be an efficacious intervention strategy is unknown. Here we demonstrate elevated abundance of senescence biomarkers in IPF lung, with p16 expression increasing with disease severity. We show that the secretome of senescent fibroblasts, which are selectively killed by a senolytic cocktail, dasatinib plus quercetin (DQ), is fibrogenic. Leveraging the bleomycin-injury IPF model, we demonstrate that early-intervention suicide-gene-mediated senescent cell ablation improves pulmonary function and physical health, although lung fibrosis is visibly unaltered. DQ treatment replicates benefits of transgenic clearance. Thus, our findings establish that fibrotic lung disease is mediated, in part, by senescent cells, which can be targeted to improve health and function.
Overview
CoChat Summary
## TL;DR
This study links cellular senescence to idiopathic pulmonary fibrosis (IPF) by showing that senescence markers rise with disease severity in human lung tissue and that senescent fibroblast secretions are profibrotic. In a bleomycin mouse model, clearing senescent cells improved lung function and physical health, and dasatinib plus quercetin (DQ) reproduced the benefits of transgenic senescent-cell ablation.
## Key findings
- In human IPF lung samples, CDKN2A (p16) was significantly upregulated and increased with disease severity; higher pulmonary p16 expression correlated with reduced FVC, diffusion capacity, and SF-12 physical component score.
- In IPF tissue, p16-positive epithelial cells and fibroblasts were found in fibroblastic foci and honeycomb lung, and TAF-positive cells / γH2A.X foci were significantly increased relative to controls.
- In the bleomycin mouse model, lung injury increased whole-lung p16 expression by threefold, and SASP-related transcripts including Mcp1, Il6, Mmp12, Col1a1, and Tgfβ rose after bleomycin exposure.
- Senescent fibroblast conditioned medium was fibrogenic in vitro: it increased αSMA positivity to 62% vs 21% with control conditioned medium, increased traction forces, and induced fibrosis genes such as ACTA2, COL1A1, COL1A2, and FN1.
- In mice, senescent-cell clearance improved pulmonary/physical outcomes: Penh rose about twofold after bleomycin and was diminished by AP or DQ; lung compliance fell by 40% in vehicle-treated bleomycin mice but only 15% with AP or DQ; body weight loss averaged 3.6 g with vehicle vs about 1.6 g with AP/DQ; treadmill distance to exhaustion was >37% further with AP/DQ than vehicle.
- The paper states that histological fibrosis reductions did not reach statistical significance, despite functional benefits.
## Methods
- Human data came from LTRC control and IPF lung tissue samples, including microarray and RNA-seq datasets; the paper reports IPF n=27 and control n=10 for p16 immunohistochemistry, and transcriptome analyses stratified by FVC severity.
- The mouse study used male Ink-Attac mice given aerosolized intratracheal bleomycin (2 U/kg) or PBS, then randomized to AP20187, dasatinib plus quercetin (DQ), or vehicle at either an early prevention timepoint or a later treatment timepoint.
- Analyses included FACS of lung fibroblasts, epithelial cells, and endothelial cells, immunohistochemistry / immunofluorescence, conditioned-medium assays in IMR90 fibroblasts, traction force microscopy, RT-PCR, and statistical modeling with regression and multiple-comparison correction.
## Limitations
- The paper states that the bleomycin model spontaneously resolves, with resolution varying by factors such as genetic background and microbiome, which limits interpretation of late-stage effects.
- The authors state that they could not disentangle senescence-dependent from senescence-independent events governing fibrosis resolution.
- Lung fibrosis histology did not improve significantly after senescent-cell clearance, despite functional gains; the paper itself notes this may reflect the short time course and heterogeneity of the bleomycin model.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
13 Valid · 0 Not valid · 8 Not checked · 94 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Through secretion of the senescence-associated secretory phenotype (SASP), a broad repertoire of cytokines, chemokines, matrix remodelling proteases and growth factors, senescent cells paracrinely promote proliferation and tissue deterioration8.”
§ Cellular senescence mediates fibrotic pulmonary disease > Abstract
What the sources say
- Partly supportedcites [8] van Deursen, J. M. The role of senescent cells in ageing. Nature 509, 439–446 (2014). sourceExperimental — accuracy not yet measured
In “Senescence is a multi-step evolving process” (page unavailable), the paper says SASP-mediated paracrine signalling affects cell proliferation. In “Senescence in ageing and age-related disease” (page unavailable), it says SASP components are thought to promote proliferation of neoplastic cells and may intensify age-related tissue deterioration. The citing sentence presents those qualified effects as established and general. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Cellular senescence is an evolutionarily conserved state of stable replicative arrest induced by pro-ageing stressors also implicated in IPF pathogenesis, including telomere attrition, oxidative stress, DNA damage and proteome instability.”
§ Cellular senescence mediates fibrotic pulmonary disease > Abstract
What the sources say
- Partly supportedcites [8] van Deursen, J. M. The role of senescent cells in ageing. Nature 509, 439–446 (2014). sourceExperimental — accuracy not yet measured
The Abstract and 'Senescence is a multi-step evolving process' describe growth arrest, including a transition to stable cell-cycle arrest. 'Causes and effector pathways of senescence' identifies telomere erosion, DNA lesions, reactive oxygen species and proteotoxic stress as senescence-related stressors. The cited passages do not establish that senescence is evolutionarily conserved or that these stressors are implicated in IPF pathogenesis; the paper also distinguishes replicative senescence from other forms of senescence. (LLM, conf=0.86)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Critically, impaired capacity to resolve fibrotic bleomycin injury has been associated with accumulation of apoptosis-resistant, senescent myofibroblasts3.”
§ Cellular senescence mediates fibrotic pulmonary disease > Results > Senescent cell retention impairs fibrosis resolution Taken together, our in vivo results strongly support the hypothesis that elimination of senescent cells improves fibrotic pulmonary disease when treatment is initiated at the onset of pathogenesis. We next sought to test the clinically important question of whether senescent cell clearance provides comparable benefit when initiated at a timepoint when pathology has fully developed. Ink-Attac mice contained a strong senescent signature in lung fibroblasts and epithelial cells 2 weeks post-bleomycin challenge (Fig. 2), a timepoint of well-established fibrotic remodelling in the lung15. Accordingly, we administered a single dose of bleomycin or PBS through aerosolized intratracheal administration to Ink-Attac mice. Two weeks post challenge, we randomized bleomycin-exposed mice to AP, DQ or vehicle treatment groups based on change in body weight and non-invasively measured airway resistance (Penh). Mice were treated for 2 weeks and were killed 4 weeks following bleomycin or PBS exposure (Fig. 5a). Body weight monitoring revealed that, similar to our previous experiments (Fig. 4f), mice that received bleomycin lost substantial body mass, relative to mice that received PBS. Upon treatment initiation on day 14, mean body weight of mice treated with AP plateaued, while vehicle-treated, bleomycin-exposed counterparts continued to lose weight (Fig. 5a), suggestive of physical benefit afforded by senescent cell clearance, even when treatment is initiated in later-stage disease. Spontaneous resolution is an inherent limitation of the bleomycin IPF model, with the rate and variability of bleomycin-induced pathology resolution dependent on complex factors, including genetic background and the microbiome3839. Indeed, both endpoint compliance (Supplementary Fig. 6) and comparison of Penh airway resistance at endpoint (4 weeks post challenge) to measures taken at the treatment randomization timepoint (2 weeks post challenge) revealed appreciable, albeit variable, improvement in all bleomycin-exposed groups, including vehicle-treated mice, with AP-treated mice showing greatest improvement (Fig. 5b). Thus, in our hands, the 3–4-week-period following a single bleomycin exposure represents a pivotal window of natural resolution (Figs 4 and 5a,b). Critically, impaired capacity to resolve fibrotic bleomycin injury has been associated with accumulation of apoptosis-resistant, senescent myofibroblasts3. As we were unable to disentangle senescence-dependent and -independent events governing resolution, we queried whether p16 expression, a measure of senescent burden, was associated with indicators of disease persistence. Impaired lung function, as measured by endpoint airway resistance (Penh) (Fig. 5c) and airway compliance (Fig. 5d), correlated significantly with p16 transcript abundance. This finding is consistent with associations drawn in humans, in which increased p16 expression correlated significantly with reduced FVC, pulmonary diffusion capacity and physical function (Supplementary Fig. 1). Similarly, in bleomycin-exposed mice, expression of the inflammatory and fibrogenic SASP factors Mcp1 (Fig. 5e), Pai1 (Fig. 5f), Mmp10 (Fig. 5g) and Col1a1 (Fig. 5h) robustly correlated with p16 transcriptional activation. These results further support the notion that the presence and activities of senescent cells may dictate resolution capacity following bleomycin-induced pathology.
What the sources say
- Supportedcites [3] Hecker, L. et al. Reversal of persistent fibrosis in aging by targeting Nox4-Nrf2 redox imbalance. Sci. Transl. Med. 6, 231ra247 (2014). source
The Introduction states that aged mice have impaired fibrosis resolution associated with senescent, apoptosis-resistant myofibroblasts. The Results identify bleomycin as the lung-injury model and report accumulation of senescent myofibroblasts in aged mice with persistent fibrosis. Page numbers are not provided in our copy. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Senescence was confirmed by expression profiling (p16, SASP factors) and/or SA-β-gal staining32 21 days post radiation.”
§ Cellular senescence mediates fibrotic pulmonary disease > Methods > Cell culture For experiments employing radiation-induced senescence, IMR90 (passages 5–7; ATCC, catalogue number CCL-186) and primary human fibroblasts (passages 3–6) were exposed to 10 Gy radiation or sham conditions using a RS2000 X-Ray Irradiator (RAD Source Technologies, Suwanee, GA). Normal bronchial epithelial cells (passages 4–7, Lot 7F3000, Lonza, Walkersville, MD) were exposed to 5 Gy or sham conditions. Senescence was confirmed by expression profiling (p16, SASP factors) and/or SA-β-gal staining32 21 days post radiation. For SA-β-gal staining, cells were fixed for 10 min in 2% formaldehyde+0.2% glutaraldehyde in PBS at room temperature. Cells were rinsed with PBS and incubated overnight in SA-β-gal staining solution containing the following: 1 mg ml−1 X-gal, 40 mM citric acid/sodium phosphate buffer pH 6.0, 5 mM potassium ferrocyanide, 5 mM potassium ferricyanide, 150 mM sodium chloride and 2 mM magnesium chloride in water. Cells were then rinsed in PBS and stored at 4 °C until imaging. Media applied 20 days post irradiation (or sham) was collected 24 h later and was diluted with NCM to reflect equivalent source cell concentrations. ProcartaPlex immunoassays (Affymetrix eBioscience) were used for CM secretome composition assessment, according to the manufacturer's specifications. Non-irradiated IMR90 cells (passages 5–7) were treated with NCM, NCM+2 ng ml−1 TGFβ, CCM or SASP-CM and applied to downstream analyses as indicated. Primary human fibroblasts collected from human patients were authenticated through αSMA staining. For senolytic treatment, sham and irradiated primary human fibroblasts were treated with indicated concentrations of DQ or navitoclax for 3 days, starting at day 20 post irradiation or sham exposure. Cell viability after drug treatment was measured by ATPLite Kits (PerkinElmer; Waltham, MA) performed according the manufacturer's instructions. Luminescence was read using a multi-scan plate reader (Fisher). For experiments utilizing etoposide-induced senescence, IMR90 human lung fibroblasts (passage 10; ATCC) were treated for 48 h with 20 μM etoposide (Enzo Life Sciences, Farmingdale, NY). Etoposide was removed and replaced with fresh media. Six days after etoposide removal, approximately 60% of IMR90 cells were SA-β-gal positive. Cells were treated for 48 h with 20 μM D+15 μM Q or 10 μM navitoclax (or untreated control) and the percentage of SA-β-gal-positive cells was determined using a C12FDG-based senescence assay described as follows46. Briefly, etoposide-treated senescent IMR90 cells were seeded at a concentration of 5 × 103 cells per well in 96-well plates 24 h before treatment. Following addition of the drugs, the cells were incubated for 48 h under 20% O2 oxygen conditions. For fluorescence analysis of SA-β-gal activity, cells were incubated for 1 h with 100 nM Bafilomycin A1 (Calbiochem, San Diego, CA). Next, 10 μM C12FDG (Setareh Biotech, Eugene, OR) was added to the culture medium and the cells were incubated for 1.5–2 h. Ten minutes before analysis, the DNA intercalating Hoechst dye (2 μg ml−1) was added to the cells. For quantitative analysis of cell number (Hoechst staining) and number of C12FDG-positive senescent cells, a laser-based line scanning confocal imager IN Cell 6000 Analyzer was used. All samples were analysed in duplicate with three to five fields per well.
What the sources say
- Partly supportedcites [32] Baker, D. J. et al. Naturally occurring p16(Ink4a)-positive cells shorten healthy lifespan. Nature 530, 184–189 (2016). sourceExperimental — accuracy not yet measured
In “ATTAC clears senescent adipocyte progenitor cells” (page unavailable), the paper identifies cells using p16 expression, other senescence markers, and SAβ-Gal staining. It studies naturally occurring senescent cells, however, and does not support the claim’s 21-day post-radiation condition. (LLM, conf=0.86)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Importantly, CM collected from irradiated bronchiolar epithelial cells did not activate a fibrogenic response, as measured by αSMA fibrotic activation of naive IMR90 cells (Supplementary Fig. 2), suggesting that cell-type-specific SASP composition may differentially affect pathological phenotypes within the lung.”
§ Cellular senescence mediates fibrotic pulmonary disease > Results > The secretome of senescent fibroblasts is profibrotic
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
61 more claims
Create a free account to see all 115 claims and to verify the 5 references still open.
- It may state two separate claims as one. 29
- Probably not a substantial claim. 26
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This is in agreement with a recent report showing that the removal of senescent cells expressing high levels of p16INK4a can lead to fibrosis in mice101, whereas small-molecule senolytics appear to reduce fibrosis in several mouse tissues22,71,73,75,102.”
From Cellular senescence and senolytics: the path to the clinic (2022) · cites this paper as [71]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“in a mouse model of idiopathic pulmonary fibrosis (IPF), D + Q treatment improved lung compliance and reduced frailty71.”
From Cellular senescence and senolytics: the path to the clinic (2022) · cites this paper as [71]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Patients with IPF accumulate TAFs and senescence markers in lungs that increase with disease severity and activate SASP52.”
From Telomere dysfunction in ageing and age-related diseases (2022) · cites this paper as [52]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The use of various natural flavonoids, including quercetin and fisetin, either alone or in combination with dasatinib, a pan-tyrosine kinase inhibitor, can stimulate senolysis in a variety of contexts in vitro and in vivo199,207–210.”
From Cellular senescence in ageing: from mechanisms to therapeutic opportunities (2021) · cites this paper as [199]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“consistent with enhanced paracrine signaling from increased numbers of senescent neighbors and with established features of epithelial aging.23,25,32–35”
From SenCat: Cataloging human cell senescence through multi-omic profiling of multiple senescent primary cell types (2026) · cites this paper as [33]
Experimental — accuracy not yet measured
35 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Smyth, G. K. (2004) · Statistical Applications in Genetics and Molecular Biology · doi:10.2202/1544-6115.1027 · Cited by 11,829
Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders
Baker, D. J., Wijshake, T., Tchkonia, T., LeBrasseur, N. K., Childs, B. G., van de Sluis, B., Kirkland, J. L., & van Deursen, J. M. (2011) · Nature · doi:10.1038/nature10600 · Cited by 3,670
Self-citationNaturally occurring p16Ink4a-positive cells shorten healthy lifespan
Baker, D. J., Childs, B. G., Durik, M., Wijers, M. E., Sieben, C. J., Zhong, J., A. Saltness, R., Jeganathan, K. B., Verzosa, G. C., Pezeshki, A., et al. (2016) · Nature · doi:10.1038/nature16932 · Cited by 2,876 · cited 2×
“Attenuation of age-related pathologies and extension of lifespan in chronologically aged mice has been demonstrated using the same transgenic strategy 32–34 , and improvements in lung structure and function in aged mice have recently been demonstrated using a similar suicide-gene strategy 20 .”
Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment: International Consensus Statement
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.2.ats3-00 · Cited by 2,628
The role of senescent cells in ageing
van Deursen, J. M. (2014) · Nature · doi:10.1038/nature13193 · Cited by 2,623
The Achilles' heel of senescent cells: from transcriptome to senolytic drugs
Zhu, Y., Tchkonia, T., Pirtskhalava, T., Gower, A. C., Ding, H., Giorgadze, N., Palmer, A. K., Ikeno, Y., Hubbard, G. B., Lenburg, M., et al. (2015) · Aging Cell · doi:10.1111/acel.12344 · Cited by 2,584 · cited 2×
“An alternative approach to transgenic senescent cell clearance is senolytics 21,22 , which may be a tractable treatment option for humans.”
Self-citationDesmoulière, A., Geinoz, A., Gabbiani, F., & Gabbiani, G. (1993) · The Journal of cell biology · doi:10.1083/jcb.122.1.103 · Cited by 2,243
King, T. E., Pardo, A., & Selman, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60052-4 · Cited by 2,194
An Essential Role for Senescent Cells in Optimal Wound Healing through Secretion of PDGF-AA
Demaria, M., Ohtani, N., Youssef, S. A., Rodier, F., Toussaint, W., Mitchell, J. R., Laberge, R.-M., Vijg, J., Van Steeg, H., Dollé, M. E. T., et al. (2014) · Developmental Cell · doi:10.1016/j.devcel.2014.11.012 · Cited by 2,045
Senescence of Activated Stellate Cells Limits Liver Fibrosis
Krizhanovsky, V., Yon, M., Dickins, R. A., Hearn, S., Simon, J., Miething, C., Yee, H., Zender, L., & Lowe, S. W. (2008) · Cell · doi:10.1016/j.cell.2008.09.015 · Cited by 2,027
Cited by
Items 101–200 of 1,619
Cellular senescence: Molecular mechanisms and pathogenicity
Wei, W., & Ji, S. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26956 · Cited by 210
“Senescent cell clearance also reduces the expression of proinflammatory factors, including Mcp1, Mmp12, and TGF‐β, which coincides with the resolution of fibrosis (Schafer et al., 2017).”
BackgroundSenotherapeutics: emerging strategy for healthy aging and age-related disease
Kim, E.-C., & Kim, J.-R. (2019) · BMB Reports · doi:10.5483/bmbrep.2019.52.1.293 · Cited by 208
“ARDs, including cardiac aging (29), atherosclerosis (31), osteoporosis (23), pulmonary fibrosis (32), hepatic steatosis (22), and Alzheimer’s disease (24) by clearing SCs in the”
BackgroundSenolytics and senostatics as adjuvant tumour therapy
Short, S., Fielder, E., Miwa, S., & von Zglinicki, T. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.01.056 · Cited by 202
“has been associated with these changes and chronic lung disease [58,136].”
BackgroundBrandsma, C., Van den Berge, M., Hackett, T., Brusselle, G., & Timens, W. (2020) · The Journal of Pathology · doi:10.1002/path.5364 · Cited by 204
Gonzales, M. M., Garbarino, V. R., Marques Zilli, E., Petersen, R. C., Kirkland, J. L., Tchkonia, T., Musi, N., Seshadri, S., Craft, S., & Orr, M. E. (2022) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2021.62 · Cited by 203
“Moreover, disease-modifying effects were observed with a partial (35%) decrease in NFTs, which was consistent with preclinical studies of senolytic treatment for other models of aging and disease (10-16, 18, 19, 30, 54-56).”
BackgroundResultSelf-citationHohmann, M. S., Habiel, D. M., Coelho, A. L., Verri, W. A., & Hogaboam, C. M. (2019) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2017-0289oc · Cited by 202
NKG2D-CAR T cells eliminate senescent cells in aged mice and nonhuman primates
Yang, D., Sun, B., Li, S., Wei, W., Liu, X., Cui, X., Zhang, X., Liu, N., Yan, L., Deng, Y., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.add1951 · Cited by 217
“The human lung fibroblast cell lines IMR90 (catalog number CCL186) and WI38 (catalog number CCL-75) were purchased from the American Type Culture Collection (ATCC), and the HEL1 cell line was purchased from the China Infrastructure of Cell Line Resources (catalog number KCB 86024).”
MethodInfluentialStrategies targeting cellular senescence
Ovadya, Y., & Krizhanovsky, V. (2018) · Journal of Clinical Investigation · doi:10.1172/jci95149 · Cited by 200
“It also improved lung function during bleomycin-induced lung fibrosis in mice (30).”
BackgroundVascular senescence in cardiovascular and metabolic diseases
Katsuumi, G., Shimizu, I., Yoshida, Y., & Minamino, T. (2018) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2018.00018 · Cited by 196
Tian, Y., Li, H., Qiu, T., Dai, J., Zhang, Y., Chen, J., & Cai, H. (2019) · Aging Cell · doi:10.1111/acel.12858 · Cited by 198
“These findings agree with those of recent studies (Chilosi et al., 2013; Miyoshi et al., 2013; Schafer et al., 2017; Sueblinvong et al., 2012).”
BackgroundResultCellular Senescence in Postmitotic Cells: Beyond Growth Arrest
Sapieha, P., & Mallette, F. A. (2018) · Trends in Cell Biology · doi:10.1016/j.tcb.2018.03.003 · Cited by 193
Immune Clearance of Senescent Cells to Combat Ageing and Chronic Diseases
Song, P., An, J., & Zou, M.-H. (2020) · Cells · doi:10.3390/cells9030671 · Cited by 198
Senescent Cells: Emerging Targets for Human Aging and Age-Related Diseases
Song, S., Lam, E. W.-F., Tchkonia, T., Kirkland, J. L., & Sun, Y. (2020) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2020.03.008 · Cited by 195
Self-citationCalcium channel ITPR2 and mitochondria–ER contacts promote cellular senescence and aging
Ziegler, D. V., Vindrieux, D., Goehrig, D., Jaber, S., Collin, G., Griveau, A., Wiel, C., Bendridi, N., Djebali, S., Farfariello, V., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-20993-z · Cited by 194
HIV as a Cause of Immune Activation and Immunosenescence
Sokoya, T., Steel, H. C., Nieuwoudt, M., & Rossouw, T. M. (2017) · Mediators of Inflammation · doi:10.1155/2017/6825493 · Cited by 192
Selman, M., & Pardo, A. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101393 · Cited by 211
“…renal, and lung fibrotic diseases have demonstrated that in ageing, compositional and structural changes in the ECM profoundly influence cell phenotype and function contributing to disease progression throughout several mechanisms (Schafer et al., 2017; Lu et al., 2017; Sturmlechner, 2017).”
BackgroundReducing Senescent Cell Burden in Aging and Disease
Pignolo, R. J., Passos, J. F., Khosla, S., Tchkonia, T., & Kirkland, J. L. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2020.03.005 · Cited by 177
Self-citationSenotherapeutics for healthy ageing
Niedernhofer, L. J., & Robbins, P. D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.44 · Cited by 190
Self-citationConnecting aging biology and inflammation in the omics era
Walker, K. A., Basisty, N., Wilson, D. M., & Ferrucci, L. (2022) · Journal of Clinical Investigation · doi:10.1172/jci158448 · Cited by 189
“, atherosclerosis (16), osteoarthritis (17), cancer (18), myeloid skewing in the bone marrow (19), pulmonary fibrosis (20), Alzheimer’s disease and Parkinson’s disease (21–23), and insulin resistance (24).”
BackgroundCellular senescence in cancer: from mechanisms to detection
Ou, H., Hoffmann, R., González‐López, C., Doherty, G. J., Korkola, J. E., & Muñoz‐Espín, D. (2021) · Molecular Oncology · doi:10.1002/1878-0261.12807 · Cited by 190
Senescence-induced inflammation: an important player and key therapeutic target in atherosclerosis
Stojanović, S. D., Fiedler, J., Bauersachs, J., Thum, T., & Sedding, D. G. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz919 · Cited by 188
Saleh, T., Carpenter, V. J., Tyutyunyk‐Massey, L., Murray, G., Leverson, J. D., Souers, A. J., Alotaibi, M. R., Faber, A. C., Reed, J., Harada, H., et al. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12761 · Cited by 190
Kadota, T., Fujita, Y., Araya, J., Watanabe, N., Fujimoto, S., Kawamoto, H., Minagawa, S., Hara, H., Ohtsuka, T., Yamamoto, Y., et al. (2021) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12124 · Cited by 187
“Both TGF-b and WNT signaling are responsible for regulating 71 myofibroblast differentiation and cellular senescence, cellular processes that 72 have been proposed as targets with respect to IPF treatment (6, 7).”
Ogrodnik, M., Salmonowicz, H., & Gladyshev, V. N. (2019) · Aging Cell · doi:10.1111/acel.12841 · Cited by 184
Self-citationRegulation of Survival Networks in Senescent Cells: From Mechanisms to Interventions
Soto-Gamez, A., Quax, W. J., & Demaria, M. (2019) · Journal of Molecular Biology · doi:10.1016/j.jmb.2019.05.036 · Cited by 175
“spine) [35], cataracts [35], hair loss [36], osteoporosis [37], aged hematopoietic system [38], vasomotor dysfunction [39], neurodegeneration [40], pulmonary fibrosis [41], and decreased lifespan [42,43].”
BackgroundCrespo-Garcia, S., Tsuruda, P. R., Dejda, A., Ryan, R. D., Fournier, F., Chaney, S. Y., Pilon, F., Dogan, T., Cagnone, G., Patel, P., et al. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.01.011 · Cited by 182
Current and Future Treatment Landscape for Idiopathic Pulmonary Fibrosis
Bonella, F., Spagnolo, P., & Ryerson, C. (2023) · Drugs · doi:10.1007/s40265-023-01950-0 · Cited by 182
Kadota, T., Fujita, Y., Yoshioka, Y., Araya, J., Kuwano, K., & Ochiya, T. (2018) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2017.11.005 · Cited by 178
Lipids and lipid metabolism in cellular senescence: Emerging targets for age-related diseases
Zeng, Q., Gong, Y., Zhu, N., Shi, Y., Zhang, C., & Qin, L. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102294 · Cited by 175
Chung, L., Maestas, D. R., Lebid, A., Mageau, A., Rosson, G. D., Wu, X., Wolf, M. T., Tam, A. J., Vanderzee, I., Wang, X., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aax3799 · Cited by 172
The inflammatory speech of fibroblasts
Schuster, R., Rockel, J. S., Kapoor, M., & Hinz, B. (2021) · Immunological Reviews · doi:10.1111/imr.12971 · Cited by 172
Senescence as a therapeutic target in cancer and age-related diseases
McHugh, D., Durán, I., & Gil, J. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01074-4 · Cited by 197
Mitochondria, telomeres and cell senescence: Implications for lung ageing and disease
Birch, J., Barnes, P. J., & Passos, J. F. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.10.005 · Cited by 170
“related disease is an attractive concept, and no overt side effects have been recorded in control mice or ex vivo lung tissues when administered in the context of pulmonary fibrosis (Lehmann et al., 2017; Schafer et al., 2017), reports of undesirable side-effects have been recorded in human cancer patients, including…”
BackgroundResultInfluentialSelf-citationBorok, Z., Horie, M., Flodby, P., Wang, H., Liu, Y., Ganesh, S., Firth, A. L., Minoo, P., Li, C., Beers, M. F., et al. (2020) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201902-0451oc · Cited by 170
“Additionally, pan-caspase inhibitor Q-VD-OPh (Figures 7D and E19A) and senolytic drugs dasatinib (D) and quercetin (Q) (DQ) (29, 31) (Figures 7E and E19B) reduced expression of mesenchymal markers, whereas DQ reduced expression of senescence markers p21, p53, g-H2A.”
BackgroundHan, Z., Wang, K., Ding, S., & Zhang, M. (2024) · Bone Research · doi:10.1038/s41413-024-00375-z · Cited by 172
Spontaneous DNA damage to the nuclear genome promotes senescence, redox imbalance and aging
Robinson, A. R., Yousefzadeh, M. J., Rozgaja, T. A., Wang, J., Li, X., Tilstra, J. S., Feldman, C. H., Gregg, S. Q., Johnson, C. H., Skoda, E. M., et al. (2018) · Redox Biology · doi:10.1016/j.redox.2018.04.007 · Cited by 155
Self-citationClinical Review: Navitoclax as a Pro-Apoptotic and Anti-Fibrotic Agent
Mohamad Anuar, N. N., Nor Hisam, N. S., Liew, S. L., & Ugusman, A. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.564108 · Cited by 168
Senescent cell turnover slows with age providing an explanation for the Gompertz law
Karin, O., Agrawal, A., Porat, Z., Krizhanovsky, V., & Alon, U. (2019) · Nature Communications · doi:10.1038/s41467-019-13192-4 · Cited by 151
Potential role of senescent macrophages in radiation-induced pulmonary fibrosis
Su, L., Dong, Y., Wang, Y., Wang, Y., Guan, B., Lu, Y., Wu, J., Wang, X., Li, D., Meng, A., et al. (2021) · Cell Death & Disease · doi:10.1038/s41419-021-03811-8 · Cited by 167
Discovery, development, and future application of senolytics: theories and predictions
Wissler Gerdes, E. O., Zhu, Y., Tchkonia, T., & Kirkland, J. L. (2020) · The FEBS Journal · doi:10.1111/febs.15264 · Cited by 160
Self-citationGuan, R., Yuan, L., Li, J., Wang, J., Li, Z., Cai, Z., Guo, H., Fang, Y., Lin, R., Liu, W., et al. (2022) · European Respiratory Journal · doi:10.1183/13993003.02307-2021 · Cited by 167
“Senescence‐associated biomarkers, including p16, p21, p53 and senescence-associated SA-β-gal activity, are higher in fibroblasts of IPF lung tissue, which promote the fibroblast-to-myofibroblast transformation [17].”
BackgroundInfluentialTargeting aging mechanisms: pharmacological perspectives
Moskalev, A., Guvatova, Z., Lopes, I. D. A., Beckett, C. W., Kennedy, B. K., De Magalhaes, J. P., & Makarov, A. A. (2022) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2022.01.007 · Cited by 164
Confalonieri, P., Volpe, M. C., Jacob, J., Maiocchi, S., Salton, F., Ruaro, B., Confalonieri, M., & Braga, L. (2022) · Cells · doi:10.3390/cells11132095 · Cited by 164
“Interestingly, MMP1, MMP7, CCL2, CXCL1, IGFBP-2, and PAI-1 are secreted factors that have been found to be increased in patients with progressive fibrosis, as well as to be secreted by cells with evident SASP, suggesting a close mechanistic connection between IPF and cellular senescence [50,51,54] (Figure 2).”
BackgroundInfluentialFibroblast senescence in the pathology of idiopathic pulmonary fibrosis
Waters, D. W., Blokland, K. E. C., Pathinayake, P. S., Burgess, J. K., Mutsaers, S. E., Prele, C. M., Schuliga, M., Grainge, C. L., & Knight, D. A. (2018) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00037.2018 · Cited by 163
Turning back time with emerging rejuvenation strategies
Mahmoudi, S., Xu, L., & Brunet, A. (2019) · Nature Cell Biology · doi:10.1038/s41556-018-0206-0 · Cited by 161
Senescence and senotherapeutics: a new field in cancer therapy
Myrianthopoulos, V., Evangelou, K., Vasileiou, P. V. S., Cooks, T., Vassilakopoulos, T. P., Pangalis, G. A., Kouloukoussa, M., Kittas, C., Georgakilas, A. G., & Gorgoulis, V. G. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.08.006 · Cited by 160
Regulation of epithelial transitional states in murine and human pulmonary fibrosis
Wang, F., Ting, C., Riemondy, K. A., Douglas, M., Foster, K., Patel, N., Kaku, N., Linsalata, A., Nemzek, J., Varisco, B. M., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci165612 · Cited by 162
Yu, Z., Xu, C., Song, B., Zhang, S., Chen, C., Li, C., & Zhang, S. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04554-0 · Cited by 164
“Additionally, senescent fibroblasts can induce senescence in neighboring fibroblasts, leading to an exacerbation of senescence-associated fibrosis [59].”
BackgroundConley, S. M., Hickson, L. J., Kellogg, T. A., McKenzie, T., Heimbach, J. K., Taner, T., Tang, H., Jordan, K. L., Saadiq, I. M., Woollard, J. R., et al. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00197 · Cited by 158
Self-citationMitochondrial dynamics and mitophagy in lung disorders
Sharma, A., Ahmad, S., Ahmad, T., Ali, S., & Syed, M. A. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119876 · Cited by 158
Itaconate controls the severity of pulmonary fibrosis
Ogger, P. P., Albers, G. J., Hewitt, R. J., O’Sullivan, B., Powell, J. E., Calamita, E., Ghai, P., Walker, S. A., McErlean, P. K., Saunders, P., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.abc1884 · Cited by 161
Rana, T., Jiang, C., Liu, G., Miyata, T., Antony, V., Thannickal, V. J., & Liu, R.-M. (2020) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2019-0071oc · Cited by 157
Hecker, L. (2018) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00275.2017 · Cited by 153
“DQ was also evaluated in the murine model of bleomycin-induced fibrosis and was reported to decrease senescence and improve pulmonary function, although lung fibrosis was unaltered (110).”
BackgroundCOVID-19 and cellular senescence
Schmitt, C. A., Tchkonia, T., Niedernhofer, L. J., Robbins, P. D., Kirkland, J. L., & Lee, S. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-022-00785-2 · Cited by 153
Self-citationIdiopathic Pulmonary Fibrosis: Aging, Mitochondrial Dysfunction, and Cellular Bioenergetics
Zank, D. C., Bueno, M., Mora, A. L., & Rojas, M. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00010 · Cited by 150
Pharmacotherapy and adjunctive treatment for idiopathic pulmonary fibrosis (IPF)
Saito, S., Alkhatib, A., Kolls, J. K., Kondoh, Y., & Lasky, J. A. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.04.62 · Cited by 148
Dorronsoro, A., Santiago, F. E., Grassi, D., Zhang, T., Lai, R. C., McGowan, S. J., Angelini, L., Lavasani, M., Corbo, L., Lu, A., et al. (2021) · Aging Cell · doi:10.1111/acel.13337 · Cited by 153
“An interactome was compiled from raw miRNA- target data using the Cytoscape bioinformatics software platform (Shannon et al., 2003).”
MethodSelf-citationCellular senescence impairs the reversibility of pulmonary arterial hypertension
van der Feen, D. E., Bossers, G. P. L., Hagdorn, Q. A. J., Moonen, J.-R., Kurakula, K., Szulcek, R., Chappell, J., Vallania, F., Donato, M., Kok, K., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw4974 · Cited by 150
Chen, H., Chen, H., Liang, J., Gu, X., Zhou, J., Xie, C., Lv, X., Wang, R., Li, Q., Mao, Z., et al. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-019-0371-7 · Cited by 149
“These factors lead to symptoms including frailty, fatigue, weight loss, and shortened walking distance and lifespan 1,2,29,30 .”
BackgroundEnvironmental Exposures and Asthma Development: Autophagy, Mitophagy, and Cellular Senescence
Sachdeva, K., Do, D. C., Zhang, Y., Hu, X., Chen, J., & Gao, P. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02787 · Cited by 147
“Both COPD and idiopathic pulmonary fibrosis (IPF) are increased in prevalence with age and have been associated with senescence (174, 175).”
BackgroundEliminating Senescent Cells Can Promote Pulmonary Hypertension Development and Progression
Born, E., Lipskaia, L., Breau, M., Houssaini, A., Beaulieu, D., Marcos, E., Pierre, R., Do Cruzeiro, M., Lefevre, M., Derumeaux, G., et al. (2023) · Circulation · doi:10.1161/circulationaha.122.058794 · Cited by 148
Wang, B., Wang, L., Gasek, N. S., Zhou, Y., Kim, T., Guo, C., Jellison, E. R., Haynes, L., Yadav, S., Tchkonia, T., et al. (2021) · Nature Aging · doi:10.1038/s43587-021-00107-6 · Cited by 145
Self-citationSummer, R., Shaghaghi, H., Schriner, D., Roque, W., Sales, D., Cuevas-Mora, K., Desai, V., Bhushan, A., Ramirez, M. I., & Romero, F. (2019) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00244.2018 · Cited by 143
“However, elevated levels of mTORC1 have also been de- AJP-Lung Cell Mol Physiol • doi:10.1152/ajplung.00244.2018 • www.ajplung.org scribed in the lungs of patients with various other, more common respiratory conditions, including IPF and COPD (13, 41, 46).”
BackgroundInfluentialPAD4 deficiency improves bleomycin-induced neutrophil extracellular traps and fibrosis in mouse lung
Suzuki, M., Ikari, J., Anazawa, R., Tanaka, N., Katsumata, Y., Shimada, A., Suzuki, E., & Tatsumi, K. (2020) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2019-0433oc · Cited by 143
Cellular Senescence Promotes Skin Carcinogenesis through p38MAPK and p44/42MAPK Signaling
Alimirah, F., Pulido, T., Valdovinos, A., Alptekin, S., Chang, E., Jones, E., Diaz, D. A., Flores, J., Velarde, M. C., Demaria, M., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-0108 · Cited by 128
Ness, K. K., Kirkland, J. L., Gramatges, M. M., Wang, Z., Kundu, M., McCastlain, K., Li-Harms, X., Zhang, J., Tchkonia, T., Pluijm, S. M. F., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.7467 · Cited by 140
“Although published literature describing effective exercise intervention among children with, or who have survived, cancer is limited, data indicate that survivors can gain lean mass, strength, and walking speed.(40,150-155) However, adherence to exercise is problematic,(156) even in healthy populations.”
BackgroundSelf-citationThe costs and benefits of senotherapeutics for human health
Raffaele, M., & Vinciguerra, M. (2022) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(21)00300-7 · Cited by 140
Mechanisms of lung disease development in rheumatoid arthritis
Wang, D., Zhang, J., Lau, J., Wang, S., Taneja, V., Matteson, E. L., & Vassallo, R. (2019) · Nature Reviews Rheumatology · doi:10.1038/s41584-019-0275-x · Cited by 155
Lozano-Torres, B., Estepa-Fernández, A., Rovira, M., Orzáez, M., Serrano, M., Martínez-Máñez, R., & Sancenón, F. (2019) · Nature Reviews Chemistry · doi:10.1038/s41570-019-0108-0 · Cited by 140
Poblocka, M., Bassey, A. L., Smith, V. M., Falcicchio, M., Manso, A. S., Althubiti, M., Sheng, X., Kyle, A., Barber, R., Frigerio, M., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-99852-2 · Cited by 137
TGF-β as A Master Regulator of Aging-Associated Tissue Fibrosis
Ren, L.-L., Miao, H., Wang, Y.-N., Liu, F., Li, P., & Zhao, Y.-Y. (2023) · Aging and disease · doi:10.14336/ad.2023.0222 · Cited by 139
Li, M., You, L., Xue, J., & Lu, Y. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00522 · Cited by 137
Senescence and the tumor-immune landscape: Implications for cancer immunotherapy
Chibaya, L., Snyder, J. T., & Ruscetti, M. A. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.02.005 · Cited by 161
Identifying specific functional roles for senescence across cell types
(2024) · doi:10.1016/j.cell.2024.09.021 · Cited by 139
From ARDS to pulmonary fibrosis: the next phase of the COVID-19 pandemic?
Michalski, J. E., Kurche, J. S., & Schwartz, D. A. (2021) · Translational research · doi:10.1016/j.trsl.2021.09.001 · Cited by 145
“Accelerated aging and cellular senescence have long been implicated in pulmonary fibrosis, and a variety of mechanisms have been associated including both genetic and environmental factors.(88,89) In human tissue,(88,90-92) animal models,(88,92) and in vitro cultures,(93) markers of cellular senescence are increased i…”
BackgroundLelarge, V., Capelle, R., Oger, F., Mathieu, T., & Le Calvé, B. (2024) · npj Aging · doi:10.1038/s41514-024-00138-4 · Cited by 140
Targeting Oxidative Stress as a Therapeutic Approach for Idiopathic Pulmonary Fibrosis
Estornut, C., Milara, J., Bayarri, M. A., Belhadj, N., & Cortijo, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.794997 · Cited by 161
“human fibroblasts demonstrated that treatment with this senolytic combination attenuates fibrotic mediator expression, such as senescence-associated secretory phenotype factor and extracellular matrix markers (Lehmann et al., 2017; Schafer et al., 2017).”
BackgroundBiomarkers in idiopathic pulmonary fibrosis
Drakopanagiotakis, F., Wujak, L., Wygrecka, M., & Markart, P. (2018) · Matrix Biology · doi:10.1016/j.matbio.2018.01.023 · Cited by 132
Secretion of leukotrienes by senescent lung fibroblasts promotes pulmonary fibrosis
Wiley, C. D., Brumwell, A. N., Davis, S. S., Jackson, J. R., Valdovinos, A., Calhoun, C., Alimirah, F., Castellanos, C. A., Ruan, R., Wei, Y., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.130056 · Cited by 132
“Furthermore, limiting the number of these senescent cells is beneficial in controlling the extent of remodeling in experimental models of lung injury (11-15).”
BackgroundChronic WNT/β-catenin signaling induces cellular senescence in lung epithelial cells
Lehmann, M., Hu, Q., Hu, Y., Hafner, K., Costa, R., van den Berg, A., & Königshoff, M. (2020) · Cellular Signalling · doi:10.1016/j.cellsig.2020.109588 · Cited by 147
“Senolytics have been effectively shown to attenuate disease in mouse models of various diseases, including pulmonary fibrosis [7,8,14,15] with first in human studies currently being performed [63].”
BackgroundInfluentialTargeting Cardiac Stem Cell Senescence to Treat Cardiac Aging and Disease
Cianflone, E., Torella, M., Biamonte, F., De Angelis, A., Urbanek, K., Costanzo, F. S., Rota, M., Ellison-Hughes, G. M., & Torella, D. (2020) · Cells · doi:10.3390/cells9061558 · Cited by 132
Walsh, S. L. F., Mackintosh, J. A., Calandriello, L., Silva, M., Sverzellati, N., Larici, A. R., Humphries, S. M., Lynch, D. A., Jo, H. E., Glaspole, I., et al. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202112-2684oc · Cited by 145
Role of Cellular Senescence in Type II Diabetes
Narasimhan, A., Flores, R. R., Robbins, P. D., & Niedernhofer, L. J. (2021) · Endocrinology · doi:10.1210/endocr/bqab136 · Cited by 133
Self-citationCalcium signaling and cellular senescence
Martin, N., & Bernard, D. (2017) · Cell Calcium · doi:10.1016/j.ceca.2017.04.001 · Cited by 138
Justice, J. N., Gregory, H., Tchkonia, T., LeBrasseur, N. K., Kirkland, J. L., Kritchevsky, S. B., & Nicklas, B. J. (2018) · The Journals of Gerontology: Series A · doi:10.1093/gerona/glx134 · Cited by 129
Self-citationOxidation resistance 1 is a novel senolytic target
Zhang, X., Zhang, S., Liu, X., Wang, Y., Chang, J., Zhang, X., Mackintosh, S. G., Tackett, A. J., He, Y., Lv, D., et al. (2018) · Aging Cell · doi:10.1111/acel.12780 · Cited by 127
Targeting Senescent Cells for a Healthier Aging: Challenges and Opportunities
Song, S., Tchkonia, T., Jiang, J., Kirkland, J. L., & Sun, Y. (2020) · Advanced Science · doi:10.1002/advs.202002611 · Cited by 129
Self-citationUpregulation of PD-L1 in Senescence and Aging
Onorati, A., Havas, A. P., Lin, B., Rajagopal, J., Sen, P., Adams, P. D., & Dou, Z. (2022) · Molecular and Cellular Biology · doi:10.1128/mcb.00171-22 · Cited by 129
“orates disease severity of pulmonary fibrosis (47, 48).”
BackgroundExercise reduces circulating biomarkers of cellular senescence in humans
Englund, D. A., Sakamoto, A. E., Fritsche, C. M., Heeren, A. A., Zhang, X., Kotajarvi, B. R., Lecy, D. R., Yousefzadeh, M. J., Schafer, M. J., White, T. A., et al. (2021) · Aging Cell · doi:10.1111/acel.13415 · Cited by 125
Self-citationMechanisms for the Resolution of Organ Fibrosis
Horowitz, J. C., & Thannickal, V. J. (2018) · Physiology · doi:10.1152/physiol.00033.2018 · Cited by 144
Targeting senescent cells: approaches, opportunities, challenges
von Kobbe, C. (2019) · Aging · doi:10.18632/aging.102557 · Cited by 127
“Tissues from IPF patients display some phenotypical characteristics of senescent cells, and when these cells were removed by senolytics, pulmonary functions improved [104].”
BackgroundRegulation of cellular senescence by extracellular matrix during chronic fibrotic diseases
Blokland, K. E. C., Pouwels, S. D., Schuliga, M., Knight, D. A., & Burgess, J. K. (2020) · Clinical Science · doi:10.1042/cs20190893 · Cited by 128
Kulkarni, A. S., Aleksić, S., Berger, D. M., Sierra, F., Kuchel, G. A., & Barzilai, N. (2022) · Aging Cell · doi:10.1111/acel.13596 · Cited by 137
“…of senescent cells or downregulating inflammation in older mice and thereby preventing aging- related cognitive, mobility declines, frailty, vasomotor, uterine dysfunction, or fibrosis (Cavalcante et al., 2020; Farr et al., 2017; Roos et al., 2016; Schafer et al., 2017; P. Zhang et al., 2019).”
BackgroundEmerging use of senolytics and senomorphics against aging and chronic diseases
Martel, J., Ojcius, D. M., Wu, C., Peng, H., Voisin, L., Perfettini, J., Ko, Y., & Young, J. D. (2020) · Medicinal Research Reviews · doi:10.1002/med.21702 · Cited by 127
“Similarly, a previous study showed that the cocktail of quercetin and dasatinib reduced senescent cell burden and lung fibrosis in bleomycin‐treated mice.(57) In addition, polysaccharides derived from the medicinal fungi Ganoderma lucidum and H.”
ResultSenolytics for Cancer Therapy: Is All that Glitters Really Gold?
Carpenter, V. J., Saleh, T., & Gewirtz, D. A. (2021) · Cancers · doi:10.3390/cancers13040723 · Cited by 124
“The D+Q combination has been shown to clear senescent cells in vitro and in vivo in a variety of senescence or aging-related models including chronic atherosclerotic vascular disease [68,69], radiation- or bleomycin-induced lung fibrosis [70], aging-”
BackgroundCellular Senescence: Pathogenic Mechanisms in Lung Fibrosis
Parimon, T., Hohmann, M. S., & Yao, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126214 · Cited by 134
“Senescent IPF fibroblasts secrete numerous pro-inflammatory cytokines/chemokines, pro-fibrotic factors, and reactive oxygen species [41,94,96,97].”
BackgroundInfluentialFarr, J. N., Rowsey, J. L., Eckhardt, B. A., Thicke, B. S., Fraser, D. G., Tchkonia, T., Kirkland, J. L., Monroe, D. G., & Khosla, S. (2019) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3729 · Cited by 122
“Indeed, in recent years, several groups have shown that genetic or pharmacological selective elimination of senescent cells has a remarkable therapeutic impact across multiple organ systems in mouse models of aging and chronic pathological diseases, including metabolic dysfunction,((29)) atherosclerosis/ cardiovascula…”
Self-citationKang, C. (2019) · PubMed · doi:10.14348/molcells.2019.0298 · Cited by 121
“, 2017), idiopathic pulmonary fibrosis (Schafer et al., 2017), atherosclerosis (Childs et al.”
BackgroundBaek, A.-R., Hong, J., Song, K. S., Jang, A., Kim, D.-J., Chin, S., & Park, S. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-00545-z · Cited by 132
Lipids as Regulators of Cellular Senescence
Hamsanathan, S., & Gurkar, A. U. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.796850 · Cited by 137
“Cellular senescence, in summary is a cell-fate process associated with several age-related pathologies including frailty, Alzheimer’s disease, Parkinson disease, atherosclerosis, idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease, and osteoarthritis (Schafer et al., 2017; Chinta et al., 2018; Sagiv e…”
Background
Metadata
- Authors
- Schafer, M. J., White, T. A., Iijima, K., Haak, A. J., Ligresti, G., Atkinson, E. J., Oberg, A. L., Birch, J., Salmonowicz, H., Zhu, Y., Mazula, D. L., Brooks, R. W., Fuhrmann-Stroissnigg, H., Pirtskhalava, T., Prakash, Y. S., Tchkonia, T., Robbins, P. D., Aubry, M. C., Passos, J. F., Kirkland, J. L., Tschumperlin, D. J., Kita, H., & LeBrasseur, N. K.
- Affiliations
- Mayo Clinic (US)
- Newcastle University (GB)
- Scripps Research Institute (US)
- Corresponding author
- LeBrasseur, Nathan K.
- ORCID
- Venue
- Nature Communications
- Published
- 2017-02-23
- Volume
- 8
- Issue
- 1
- Pages
- 14532-14532
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC5331226
- OpenAlex
- W2591114726
- Cited by
- 1,613
- References
- 52
- Citations by year
- 2026: 195 · 2025: 205 · 2024: 193 · 2023: 193 · 2022: 192 · 2021: 181 · 2020: 176 · 2019: 128 · 2018: 107 · 2017: 42
- FWCI
- 91.58
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Newcastle University ePrints (Newcastle Univesity) (cc-by)
- Funders
- Mayo Clinic (UL1-TR000135)
- Glenn Foundation for Medical Research
- Louisiana Transportation Research Center
- Georgia Clinical and Translational Science Alliance (UL1 TR000135)
- Noaber Foundation
- Fondation pour la Recherche Médicale
- National Institutes of Health (UL1TR000135, 2r01hl092961-13)
- Directorate for Biological Sciences
- Biotechnology and Biological Sciences Research Council (BB/K017314/1, BB/H022384/1)
- National Institute on Aging (R01AG053832, R01AG013925, R37AG013925)
- National Heart, Lung, and Blood Institute (R01-HL-092961)
- National Center for Advancing Translational Sciences
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Keywords
- cellular senescence, idiopathic pulmonary fibrosis, senolytics, senescence-associated secretory phenotype, senescent fibroblasts, p16, bleomycin-induced lung injury, interstitial pulmonary fibrosis, suicide gene therapy, lung function
- MeSH terms
- Animals, Bleomycin, Fibroblasts, Humans, Lung, Male, Biomarkers, Cellular Senescence, Cyclin-Dependent Kinase Inhibitor p16, Proteome, Mice, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.